ODI Pharma Q1-24

Starting 2024 with Significant Growth and Profitability

The third quarter was a breakthrough quarter for ODI Pharma AB (”ODI Pharma” or the ”Company”), with net sales amounting to SEK 13.9m and an EBIT margin of 11%, proving the significance of the collaboration with Synoptis Pharma and the scalable business model. ODI Pharma’s unique business model has resulted in the Company being, and expected to remain, one of the very few profitable companies in the cannabis industry. According to Analyst Group, this presents an attractive investment opportunity. With estimated net sales of SEK 127m by 2025/2026, and with an applied P/S multiple of 2.8x, a potential present value per share of SEK 17.4 (10.7) is derived in a Base scenario.

  • A Breakthrough Quarter

ODI Pharma delivered a breakthrough quarter in Q3-23/24 as net sales amounted to SEK 13.9m (0.0), the first significant sales in the Company’s history. The figures is a result of several successful deliveries of medical cannabis products to the partner Synoptis, a market leading pharmaceutical brand, which is also expected to drive continued sales growth.

  • Proof of the Scalable Business Model

Despite the strong sales during the quarter, the cost base remained stable. ODI Pharma’s cost base is largely fixed, with shipping costs expected to be the largest variable cost. Given the remained low cost base during Q3 however, shipping costs are not expected to be significant. As a result of the stable cost base in combination with strong sales, ODI Pharma delivered an EBIT margin of 11% during the quarter, and we expect the Company to deliver strong cash flows going forward.

  • A Profitable Medical Cannabis Company Creates a Unique Investment Opportunity

The medical cannabis industry is characterized by high investments required both to navigate the heavily regulated market and to invest in cultivation. Consequently, several companies in the industry struggle to demonstrate profitability. Within the applied peer group, only one company is profitable in terms of net results, highlighting the profitability challenges in the industry. ODI Pharma, however, has a different business model that does not involve investments in cultivation, thus creating a unique investment opportunity in medical cannabis as a profitable company.

  • We Raise our Valuation Range

With the Q3-report presented, we have obtained evidence that the collaboration agreement with Synoptis Pharma is a game changer for ODI Pharma, as demonstrated by the strong sales. Additionally, the cost base remained low even during this scale-up, proving the scalability of the business model, according to Analyst Group. As a result, we believe that a revaluation of ODI Pharma is justified, and we have accordingly raised our valuation range in all scenarios.




Historisk lönsamhet


Risk profil


Ledning & Styrelse

Samtliga analyser av bolag från och med år 2020 betygssätts utifrån ett nytt betygssystem - Värdedrivare, Historisk Lönsamhet och Ledning & Styrelse sträcker sig från 1 till 10, där 10 är högsta betyg. Riskprofil sträcker sig från 1 till 10, där 10 är att anse som högst risk. Aktieanalyser av bolag publicerade innan 2020 har betygssatts utifrån en annan modell.